Search results for "Inflammatory bowel diseases"

showing 10 items of 209 documents

Cytokines in Colitis-Associated Cancer: Potential Drug Targets?

2008

In inflammatory bowel disease (IBD), such as UC and CD, the development of colorectal carcinoma can be initiated through chronic inflammation, depending on the duration and severity of the disease. Growing evidence supports a role for various cytokines, released by epithelial and immune cells, in the pathogenesis of colitis associated cancer (CAC). For instance, TNF-alpha has been recently shown to promote tumor development in experimental colitis. Due to its role in the pathogenesis of IBD, TNF-alpha blockade has become one of the cornerstones of IBD therapy. Thus, anti-TNF-alpha strategies could also provide effective anti-tumor therapies. TGF-beta has been shown to attenuate an anti-tumo…

Colorectal cancerImmunologyInflammationInflammatory bowel diseasePathogenesisImmune systemT-Lymphocyte SubsetsAnimalsHumansImmunology and AllergyMedicineColitisPharmacologyInterleukin-6Tumor Necrosis Factor-alphabusiness.industryCancerGeneral MedicineColitisInflammatory Bowel Diseasesmedicine.diseaseInterleukin-12Interleukin-10ImmunologyCytokinesTumor necrosis factor alphamedicine.symptomColorectal NeoplasmsbusinessInflammation & Allergy - Drug Targets
researchProduct

P228 Cytomegalovirus Infection: is it a cause of flare-up in inflammatory bowel diseases?

2020

Abstract Background The presence of CMV in blood is quite common in patients with severe flares of ulcerative colitis (UC) and Crohn’s disease (CD) and seems to predict an adverse outcome. The impact of antiviral treatment on CMV in this setting (indications and drug options) is an unresolved issue. Our aim was to reassess the CMV role in patients with IBD hospitalised for severe exacerbations, analysing the relationship between CMV positivity, clinical characteristics, antiviral therapy and disease outcomes. Methods We evaluated a homogeneous cohort of 97 consecutive patients with IBD hospitalised from 2012 to 2018. Data regarding age, gender, smoke, familial predisposition, type of IBD, e…

Crohn's diseasebusiness.industrymedicine.medical_treatmentGastroenterologyInflammatory Bowel DiseasesGeneral Medicinemedicine.diseaseInflammatory bowel diseaseUlcerative colitisCytomegalovirus infectionImmunologymedicineFlare upBiological response modifiersbusinessColectomyJournal of Crohn's and Colitis
researchProduct

Laryngeal manifestations of Crohn's disease

2020

Crohn’s disease is a chronic inflammatory bowel disease. It should be considered a multisystemic disease due to its extra-intestinal manifestations found in 25-40% of patients with inflammatory bowel disease. Laryngeal involvement is very uncommon and the lesions in hypopharynx and larynx are edema, ulcerations and granulation tissue. Symptoms are dysphonia, dysphagia, odynophagia and airway restriction. Laryngeal manifestations of Crohn’s disease are usually successfully treated with oral steroids. We describe a 54-year-old woman who presented with dysphagia and odynophagia for 20 days. She had a history of Crohn’s disease for 6 years. Laryngoscopy revealed a cobblestone appearance of epig…

Crohn's diseasemedicine.medical_specialtySettore MED/31 - OtorinolaringoiatriaOtorhinolaryngologybusiness.industrymedicineCrohn diseaseInflammatory bowel diseasesLarynxmedicine.diseasebusinessDermatologyOtorinolaringologia
researchProduct

P717 Ustekinumab in Crohn’s disease: Real-world outcomes from the Sicilian Network for inflammatory bowel diseases (SN-IBD):–Preliminary results

2020

Abstract Background Ustekinumab is approved in Europe for the treatment of moderate-to-severe Crohn’s disease (CD) since 2016. Italian real-life data on efficacy and safety are scarce. The aim of this study was to assess effectiveness, safety and usage of Ustekinumab in an Italian cohort of patients. Methods Data of patients with moderate-to-severe CD who started Ustekinumab in Sicily were extracted from the database of the SN-IBD. Demographic data, disease-related data (disease duration, location, clinical activity) and previous therapies with biologics were collected. The primary study endpoints were steroid-free clinical remission and steroid-free clinical response at week 12, 24 and 52 …

Crohn's diseasemedicine.medical_specialtybusiness.industryInternal medicineUstekinumabGastroenterologymedicineReal world outcomesInflammatory Bowel DiseasesGeneral Medicinemedicine.diseasebusinessmedicine.drugJournal of Crohn's and Colitis
researchProduct

Physicians’ Knowledge and Application of Immunization Strategies in Patients with Inflammatory Bowel Disease: A Survey of the Italian Group for the S…

2019

<b><i>Background:</i></b> No data on European countries about knowledge and application of immunization strategies in patients with inflammatory bowel disease (IBD) are available. <b><i>Objectives:</i></b> We designed a questionnaire aimed at exploring these issues among Italian gastroenterologists dealing with adult and paediatric IBD. <b><i>Methods:</i></b> An anonymous, 24-item, questionnaire was sent via e-mail to all members of the Italian Group for the study of Inflammatory Bowel Disease. Three sets of questions were formulated: (1) Characteristics of respondents; (2) General opinions on the role of vaccines in IB…

Crohn’s diseaseAdultMaleHealth Knowledge Attitudes Practicemedicine.medical_specialtyAttitude of Health PersonnelCrohn’s disease; Safety; Ulcerative colitis; VaccinesDiseaseInflammatory bowel disease03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesHumansMedicineIn patientPractice Patterns Physicians'ChildResponse rate (survey)Settore MED/12 - GastroenterologiaVaccinesCrohn's diseaseUlcerative colitibusiness.industryGastroenterologistsGastroenterologyMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseUlcerative colitisdigestive system diseasesVaccinationCrohn's diseaseUlcerative colitisItalyImmunization030220 oncology & carcinogenesisFamily medicineFemaleImmunization030211 gastroenterology & hepatologySafetybusinessDigestion
researchProduct

IMMUNOLOGICAL ASPECTS OF CROHN’S DISEASE: A REGULATORY FUNCTION OF TIM-3/ GALECTIN-9 IN LYTH1

2017

Crohn's disease (CD) is a type of inflammatory bowel disease (IBD) and its etiology is multifactorial and involves a combination of genetic and environmental factors. The interaction of these factors causes an imbalance in the microbiota, leading to the activation of several immunological and inflammatory mechanisms. From an immunological point of view, there seems to be an involvement of the TIM-3/galectin-9 pathway and of the autoregulation of LyTh1. The studies show that in patients with CD the autoregulation of LyTh1 is lost due to a reduced concentration of galectin-9 and a reduced TIM-3 expression in LyTh1. This could be one of the reasons for the state of perpetual activation in LyTh…

Crohn’s diseaselcsh:R5-920TIM-3/galectin-9.TIM-3/galectin-9Inflammatory Bowel Diseaseslcsh:Medicine (General)Euromediterranean Biomedical Journal
researchProduct

Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standard…

2020

BACKGROUND AND AIMS: Restructuring activities have been necessary during the lockdown phase of the coronavirus disease 2019 (COVID-19) pandemic. Few data are available on the post-lockdown phase in terms of health-care procedures in inflammatory bowel disease (IBD) care, and no data are available specifically from IBD units. We aimed to investigate how IBD management was restructured during the lockdown phase, the impact of the restructuring on standards of care and how Italian IBD units have managed post-lockdown activities. METHODS: A web-based online survey was conducted in two phases (April and June 2020) among the Italian Group for IBD affiliated units within the entire country. We inv…

Crohn’s diseasemedicine.medical_specialtystandards of careCOVID-19; Crohn’s disease; Inflammatory bowel disease; standards of care; therapy; ulcerative colitis; COVID-19; Critical Pathways; Disease Management; Humans; Inflammatory Bowel Diseases; Italy; Pandemics; Public Health Surveillance; Quality of Life; Surveys and Questionnaires; Standard of CareInflammatory bowel diseaseInflammatory bowel disease03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Public health surveillanceAmbulatory careSurveys and QuestionnairesPandemicmedicineHumansPublic Health SurveillanceDisease management (health)Intensive care medicinePandemicsulcerative colitisCrohn's diseasetherapybusiness.industryGastroenterologyDisease ManagementCOVID-19Standard of Caremedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisOncologyItalyCOVID-19; Crohn’s disease; Inflammatory bowel disease; standards of care; therapy; ulcerative colitis030220 oncology & carcinogenesisCritical PathwaysQuality of Life030211 gastroenterology & hepatologybusiness
researchProduct

What new endoscopic imaging modalities will become important in the diagnosis of IBD?

2008

Diagnostic Imagingmedicine.medical_specialtyColonoscopyProctoscopyInflammatory bowel diseaseEndoscopy GastrointestinalDiagnosis DifferentialIntestinal mucosamedicineMedical imagingHumansImmunology and AllergyIntestinal MucosaModalitiesmedicine.diagnostic_testbusiness.industryGastroenterologyColonoscopyInflammatory Bowel Diseasesmedicine.diseaseProctoscopyEndoscopyRadiologyDifferential diagnosisColorectal NeoplasmsbusinessInflammatory Bowel Diseases
researchProduct

Imaging techniques in inflammatory bowel disease: recent trends, questions and answers

2009

Summary Imaging techniques have undergone substantial progress in recent years and contribute significantly in the diagnosis of inflammatory bowel diseases in conjunction with patient history, clinical and laboratory examination. Modern cross-sectional imaging modalities such as computed tomography and magnetic resonance imaging allow an evaluation not only of the complete bowel wall of the small intestine, but also of extraluminal structures. They constitute a major diagnostic component in the initial workup, in stricturing or fistulizing disease and in suspected abscess. Transabdominal ultrasonography has been re-appreciated in these settings as an easy- and ready-to-use tool yielding rea…

Diagnostic Imagingmedicine.medical_specialtyContrast MediaColonoscopySensitivity and SpecificityInflammatory bowel diseaseChromoendoscopyDiagnosis DifferentialCrohn DiseasePredictive Value of TestsmedicineEndomicroscopyHumansMedical historyClinical Trials as TopicMicroscopy Confocalmedicine.diagnostic_testbusiness.industryGastroenterologyMagnetic resonance imagingColonoscopyGeneral MedicineInflammatory Bowel Diseasesmedicine.diseaseMagnetic Resonance ImagingUlcerative colitisPositron emission tomographyPositron-Emission TomographyColitis UlcerativeRadiologyTomography X-Ray ComputedbusinessGastroentérologie Clinique et Biologique
researchProduct

Abincol® (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01), an oral nutraceutical, prag…

2019

Chronic intestinal disorders (CID), including inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn’s disease, irritable bowel syndrome (IBS), and diverticular disease (DD), are diseases that relapse episodes. There is evidence that patients with CID have intestinal dysbiosis, so probiotics may counterbalance the impaired microbiota. Therefore, the current survey evaluated the efficacy and safety of Abincol®,an oral nutraceuticalcontaining a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii LDD01 (200 millions of living cells), in 3,460…

Diverticular DiseasesMaleirritable bowel syndromeLactobacillus delbrueckiiProbioticsdiverticular diseaseAdministration OralInflammatory bowel disease irritable bowel syndrome diverticular disease probiotic surveyMiddle AgedInflammatory Bowel DiseasesLactobacillusinflammatory bowel diseaseChronic DiseaseDietary SupplementsHumansFemaleOriginal ArticlesurveySelf ReportprobioticLactobacillus plantarumActa bio-medica : Atenei Parmensis
researchProduct